6
A small dose
Cambrex expands pharma services in Edinburgh
S
mall molecule company Cambrex has completed an expansion of its solid form screening and crystallisation process development facility in Edinburgh, Scotland. Described as a major expansion, the project has seen the facility’s total footprint doubled, with existing laboratory space refurbished as well. “We have seen an increase in demand for services, and specifically for largerscale crystallisation projects, so this expansion increases our efficiency and ability to respond to these requests,” said Tom Loewald, chief executive officer of Cambrex. “The work we carry out at the Edinburgh site is one part of Cambrex’s integrated drug substance offering, and the investment increases
our flexibility to work on projects at all stages of drug development.” Cambrex’s Edinburgh site provides solid form development services for drug substance and drug product. Scientists at the site work on projects both as a standalone service to pharmaceutical customers, as well as with other Cambrex sites to offer an integrated process development service. Due to the expansion, the site now holds an additional 13 fume cupboards in the laboratory, allowing the team to increase capacity and provide clients with larger process crystallisation development. The expansion will also enable Cambrex to recruit 40 more scientists with the potential for further growth in the future.
This expansion increases our efficiency and ability to respond to these requests.
CellGenix completes second phase facility expansion
M
aterials supplier CellGenix has completed the second phase of a facility expansion designed to increase capacity for cytokines. The company has implemented an automated filling and freeze-drying line, as well as increasing its bulkware production footprint, in order to increase its finished product capacity for cytokines. CellGenix hopes the expansion enables it to meet the fast-growing demand for critical raw and ancillary materials as more customers reach late-stage clinical development and
commercialisation of their cell and gene therapies. The newly expanded facility enables CellGenix to streamline its production processes. The automated filling process also provides increased accuracy and reduced risks, which further increases the safety of its preclinical and GMP cytokines.
CellGenix is now well prepared for the future growth of the cell and gene therapy market.
It follows the company’s first expansion phase in 2018, during which CellGenix added additional space and personnel in its quality control, R&D, logistics and warehouse departments. By finishing both expansion
Microbiome company awarded €2m to develop personalised probiotics delivery technology
M
icrobiome therapeutics company MyBiotics has received €2 million from the European Union’s Horizon 2020 Program. The funding will support the development of a novel technology enabling efficient delivery of personalised probiotics to prevent gutrelated diseases and recover damaged gut microbiota.
MyBiotics has developed robust culturing, fermentation and delivery technologies for generating a highly stable and diverse bacterial community that can be efficiently delivered to the gut potentially restoring microbiome equilibrium. Currently available probiotic products may have limited clinical impact due to the low
survival rates of the delivered bacteria in the gastrointestinal tract. This significantly reduces the ability of probiotic bacteria to impact the microbial diversity of the gut, thus failing to create a healthier community of bacteria. The company will now develop multi-strain collections of human bacteria, enabling the generation of effective, personalised,
